Disease Overview
Respiratory syncytial virus (RSV) is an enveloped, non-segmented, single-stranded, negative-sense RNA virus belonging to the Paramyxoviridae family. RSV is the leading cause of bronchiolitis in infants, and is estimated to be responsible for 22% of all episodes of acute lower respiratory tract infections in young children. Almost all children are infected with RSV within the first two years of life, and approximately 0.5–2.0% of infections will result in hospitalization. RSV is also recognized as a major cause of morbidity in immunosuppressed adults and the elderly.
Market Snapshot
Respiratory syncytial virus (RSV) is an enveloped, non-segmented, single-stranded, negative-sense RNA virus belonging to the Paramyxoviridae family. RSV is the leading cause of bronchiolitis in infants, and is estimated to be responsible for 22% of all episodes of acute lower respiratory tract infections in young children. Almost all children are infected with RSV within the first two years of life, and approximately 0.5–2.0% of infections will result in hospitalization. RSV is also recognized as a major cause of morbidity in immunosuppressed adults and the elderly.
Market Snapshot
- Pipeline vaccines will drive rapid growth of the RSV prophylaxis market to $3.1bn in the 2025/26 season.
- Synagis sales will remain flat until 2020/21, after which they could be threatened by infant and maternal vaccines.
- Pipeline vaccine candidates could render the use of monoclonal antibodies obsolete by the 2025/26 season.
Table of Contents
FORECAST: RESPIRATORY SYNCYTIAL VIRUS VACCINES
Overview
Recent Forecast Updates
Market Definition And Methodology
Forecast And Future Trends
Us Market Forecast
France Market Forecast
Germany Market Forecast
Italy Market Forecast
Spain Market Forecast
Uk Market Forecast
Recent Forecast Updates
Market Definition And Methodology
Forecast And Future Trends
Us Market Forecast
France Market Forecast
Germany Market Forecast
Italy Market Forecast
Spain Market Forecast
Uk Market Forecast
MARKETED DRUGS: RESPIRATORY SYNCYTIAL VIRUS
Overview
Product Profile: Synagis
Product Profile: Synagis
PIPELINE: RESPIRATORY SYNCYTIAL VIRUS
Clinical Pipeline Overview
Additional Pharma Intelligence Pipeline Resources
Product Profile (Early Stage): Ad26.Rsv.Pref
Product Profile (Early Stage): Chad155-Rsv
Product Profile (Early Stage): Gsk-3003891A
Product Profile (Early Stage): Live-Attenuated Rsv Vaccines
Product Profile (Early Stage): Medi8897
Product Profile (Early Stage): Mva-Bn Rsv
Product Profile (Early Stage): Rsv Pref Vaccine
Product Profile (Late Stage): Rsv F Vaccine
Additional Pharma Intelligence Pipeline Resources
Product Profile (Early Stage): Ad26.Rsv.Pref
Product Profile (Early Stage): Chad155-Rsv
Product Profile (Early Stage): Gsk-3003891A
Product Profile (Early Stage): Live-Attenuated Rsv Vaccines
Product Profile (Early Stage): Medi8897
Product Profile (Early Stage): Mva-Bn Rsv
Product Profile (Early Stage): Rsv Pref Vaccine
Product Profile (Late Stage): Rsv F Vaccine
LIST OF FIGURES
Figure 1: Patient-based forecasting methodology for RSV vaccines
Figure 2: Price sources and calculations, by country
Figure 3: RSV prophylaxis total market value in the US and five major EU markets, by country, 2016/17–2025/26
Figure 4: RSV prophylaxis total market value in the US and five major EU markets, by class, 2016/17–2025/26
Figure 5: Synagis sales across the five major EU markets, by country, 2016/17–2025/26
Figure 6: RSV vaccines sales in the US and five major EU markets, by risk group, 2016/17–2025/26
Figure 7: Elderly RSV vaccine sales in the US and five major EU markets, by country, 2016/17–2025/26
Figure 8: Maternal RSV vaccine sales in the US and five major EU markets, by country, 2016/17–2025/26
Figure 9: Synagis sales in the US, by risk group, 2016/17-2025/26
Figure 10: Total US RSV prophylaxis sales, by class, 2016/17-2025/26
Figure 11: RSV vaccines sales in the US, by risk group, 2016/17-2025/26
Figure 12: Synagis sales in France, by risk group, 2016/17–2025/26
Figure 13: Total France RSV prophylaxis sales, by class, 2016/17–2025/26
Figure 14: RSV vaccines sales in France, by risk group, 2016/17–2025/26
Figure 15: Synagis sales in Germany, by risk group, 2016/17–2025/26
Figure 16: Total Germany RSV prophylaxis sales, by class, 2016/17–2025/26
Figure 17: RSV vaccines sales in Germany, by risk group, 2016/17–2025/26
Figure 18: Synagis sales in Italy, by risk group, 2016/17–2025/26
Figure 19: Total Italy RSV prophylaxis sales, by class, 2016/17–2025/26
Figure 20: RSV vaccines sales in Italy, by risk group, 2016/17–2025/26
Figure 21: Synagis sales in Spain, by risk group, 2016/17–2025/26
Figure 22: Total Spain RSV prophylaxis sales, by class, 2016/17–2025/26
Figure 23: RSV vaccines sales in Spain, by risk group, 2016/17–2025/26
Figure 24: Synagis sales in the UK, by risk group, 2016/17–2025/26
Figure 25: Total UK RSV prophylaxis sales, by class, 2016/17–2025/26
Figure 26: RSV vaccines sales in the UK, by risk group, 2016/17–2025/26
Figure 27: Synagis for respiratory syncytial virus – SWOT analysis
Figure 28: Synagis sales for RSV across the US and five major EU markets, 2016/17–2025/26
Figure 29: Ad26.RSV.preF RSV for RSV prophylaxis – SWOT analysis
Figure 30: Potential sales for RSV vaccines across the US and five major EU markets, by risk group, 2016/17–2025/26
Figure 31: ChAd155-RSV for RSV prophylaxis – SWOT analysis
Figure 32: Potential sales for RSV vaccines in infants across the US and five major EU markets, by country, 2016/17–2025/26
Figure 33: GSK-3003891A for RSV prophylaxis – SWOT analysis
Figure 34: Potential sales for RSV vaccines for pregnant women across the US and five major EU markets, by country, 2016/17–2025/26
Figure 35: Live-attenuated RSV vaccines franchise for RSV prophylaxis – SWOT analysis
Figure 36: Potential sales for RSV vaccines in infants across the US and five major EU markets, by country, 2016/17–2025/26
Figure 37: MEDI8897 for RSV prophylaxis – SWOT analysis
Figure 38: MVA-BN RSV for RSV prophylaxis – SWOT analysis
Figure 39: Potential sales for RSV vaccines in the elderly across the US and five major EU markets, by country, 2016/17–2025/26
Figure 40: RSV preF vaccine for RSV prophylaxis – SWOT analysis
Figure 41: Potential sales for RSV vaccines in the elderly across the US and five major EU markets, by country, 2016/17–2025/26
Figure 42: RSV F vaccine for RSV prophylaxis – SWOT analysis
Figure 43: Potential sales for RSV vaccines across the US and five major EU markets, by risk group, 2016/17–2025/26
Figure 2: Price sources and calculations, by country
Figure 3: RSV prophylaxis total market value in the US and five major EU markets, by country, 2016/17–2025/26
Figure 4: RSV prophylaxis total market value in the US and five major EU markets, by class, 2016/17–2025/26
Figure 5: Synagis sales across the five major EU markets, by country, 2016/17–2025/26
Figure 6: RSV vaccines sales in the US and five major EU markets, by risk group, 2016/17–2025/26
Figure 7: Elderly RSV vaccine sales in the US and five major EU markets, by country, 2016/17–2025/26
Figure 8: Maternal RSV vaccine sales in the US and five major EU markets, by country, 2016/17–2025/26
Figure 9: Synagis sales in the US, by risk group, 2016/17-2025/26
Figure 10: Total US RSV prophylaxis sales, by class, 2016/17-2025/26
Figure 11: RSV vaccines sales in the US, by risk group, 2016/17-2025/26
Figure 12: Synagis sales in France, by risk group, 2016/17–2025/26
Figure 13: Total France RSV prophylaxis sales, by class, 2016/17–2025/26
Figure 14: RSV vaccines sales in France, by risk group, 2016/17–2025/26
Figure 15: Synagis sales in Germany, by risk group, 2016/17–2025/26
Figure 16: Total Germany RSV prophylaxis sales, by class, 2016/17–2025/26
Figure 17: RSV vaccines sales in Germany, by risk group, 2016/17–2025/26
Figure 18: Synagis sales in Italy, by risk group, 2016/17–2025/26
Figure 19: Total Italy RSV prophylaxis sales, by class, 2016/17–2025/26
Figure 20: RSV vaccines sales in Italy, by risk group, 2016/17–2025/26
Figure 21: Synagis sales in Spain, by risk group, 2016/17–2025/26
Figure 22: Total Spain RSV prophylaxis sales, by class, 2016/17–2025/26
Figure 23: RSV vaccines sales in Spain, by risk group, 2016/17–2025/26
Figure 24: Synagis sales in the UK, by risk group, 2016/17–2025/26
Figure 25: Total UK RSV prophylaxis sales, by class, 2016/17–2025/26
Figure 26: RSV vaccines sales in the UK, by risk group, 2016/17–2025/26
Figure 27: Synagis for respiratory syncytial virus – SWOT analysis
Figure 28: Synagis sales for RSV across the US and five major EU markets, 2016/17–2025/26
Figure 29: Ad26.RSV.preF RSV for RSV prophylaxis – SWOT analysis
Figure 30: Potential sales for RSV vaccines across the US and five major EU markets, by risk group, 2016/17–2025/26
Figure 31: ChAd155-RSV for RSV prophylaxis – SWOT analysis
Figure 32: Potential sales for RSV vaccines in infants across the US and five major EU markets, by country, 2016/17–2025/26
Figure 33: GSK-3003891A for RSV prophylaxis – SWOT analysis
Figure 34: Potential sales for RSV vaccines for pregnant women across the US and five major EU markets, by country, 2016/17–2025/26
Figure 35: Live-attenuated RSV vaccines franchise for RSV prophylaxis – SWOT analysis
Figure 36: Potential sales for RSV vaccines in infants across the US and five major EU markets, by country, 2016/17–2025/26
Figure 37: MEDI8897 for RSV prophylaxis – SWOT analysis
Figure 38: MVA-BN RSV for RSV prophylaxis – SWOT analysis
Figure 39: Potential sales for RSV vaccines in the elderly across the US and five major EU markets, by country, 2016/17–2025/26
Figure 40: RSV preF vaccine for RSV prophylaxis – SWOT analysis
Figure 41: Potential sales for RSV vaccines in the elderly across the US and five major EU markets, by country, 2016/17–2025/26
Figure 42: RSV F vaccine for RSV prophylaxis – SWOT analysis
Figure 43: Potential sales for RSV vaccines across the US and five major EU markets, by risk group, 2016/17–2025/26
LIST OF TABLES
Table 1: Number of immunized patients across the US and five major EU markets, by country (000s), 2016/17–2025/26
Table 2: Comparison of AAP Synagis prophylaxis guidelines in the 2013/14 season and in the 2014/15 season
Table 3: US RSV vaccines market forecast, 2016/17–2025/26
Table 4: Immunization coverage rates in the US, by risk group (%), 2016/17–2025/26
Table 5: France RSV vaccines market forecast, 2016/17–2025/26
Table 6: Immunization coverage rates in France, by risk group (%), 2016/17–2025/26
Table 7: Germany RSV vaccines market forecast, 2016/17–2025/26
Table 8: Immunization coverage rates in Germany, by risk group (%), 2015/16-2024/25
Table 9: Italy RSV vaccines market forecast, 2016/17–2025/26
Table 10: Immunization coverage rates in Italy, by risk group (%), 2016/17–2025/26
Table 11: Spain RSV vaccines market forecast, 2016/17–2025/26
Table 12: Immunization coverage rates in Spain, by risk group (%), 2016/17–2025/26
Table 13: UK RSV vaccines market forecast, 2016/17–2025/26
Table 14: Immunization coverage rates in the UK, by risk group (%), 2016/17–2025/26
Table 15: Synagis drug profile
Table 16: Synagis Phase III data in RSV
Table 17: Recommendations for palivizumab immunization by national authorities, 2018
Table 18: Synagis sales for RSV across the US and five major EU markets, by country ($m), 2016/17–2025/26
Table 19: Profiled pipeline products in development for RSV prophylaxis
Table 20: Ad26.RSV.preF drug profile
Table 21: Ad26.RSV.preF ongoing Phase I/II clinical trials in RSV vaccination
Table 22: Potential sales for RSV vaccines across the US and five major EU markets, by risk group ($m), 2016/17–2025/26
Table 23: ChAd155-RSV drug profile
Table 24: ChAd155-RSV completed clinical trial in RSV vaccination
Table 25: ChAd155-RSV ongoing clinical trial in RSV vaccination
Table 26: Potential sales for RSV vaccines in infants across the US and five major EU markets, by country ($m), 2016/17–2025/26
Table 27: GSK-3003891A drug profile
Table 28: GSK-3003891A completed Phase II clinical trials in RSV vaccination
Table 29: GSK-3003891A completed Phase II clinical trial in RSV vaccination
Table 30: Potential sales for RSV vaccines for pregnant women across the US and five major EU markets, by country ($m), 2016/17–2025/26
Table 31: RSV cps2 drug profile
Table 32: RSV delta NS2/delta 1313/I1314L drug profile
Table 33: RSV MEDI delta M2-2 backbone drug profile
Table 34: Summary of completed Phase I trials of RSV cps2, RSV D46/NS2/N/delta M2-2-HindIII, and RSV MEDI delta M2-2 for RSV infection
Table 35: Summary of ongoing Phase I trial of RSV delta NS2/delta 1313/I1314L and RSV MEDI delta M2-2 for RSV infection
Table 36: Potential sales for RSV vaccines in infants across the US and five major EU markets, by country ($m), 2016/17–2025/26
Table 37: MEDI8897 drug profile
Table 38: MEDI8897 Phase II clinical trial in RSV prophylaxis
Table 39: MEDI8897 Phase I trial data in RSV prophylaxis
Table 40: MVA-BN RSV drug profile
Table 41: MVA-BN RSV completed Phase I and Phase II clinical trials in RSV vaccination
Table 42: Potential sales for RSV vaccines in the elderly across the US and five major EU markets, by country ($m), 2016/17–2025/26
Table 43: RSV preF vaccine drug profile
Table 44: RSV preF vaccine Phase I/II trial data in RSV prophylaxis
Table 45: Potential sales for RSV vaccines in the elderly across the US and five major EU markets, by country ($m), 2016/17–2025/26
Table 46: RSV F vaccine profile
Table 47: RSV F vaccine Phase III Resolve data for RSV vaccination
Table 48: RSV F vaccine ongoing clinical trial in RSV vaccination
Table 49: RSV F vaccine key Phase II data in RSV vaccination
Table 50: Potential sales for RSV vaccines across the US and five major EU markets, by risk group ($m), 2016/17–2025/26
Table 2: Comparison of AAP Synagis prophylaxis guidelines in the 2013/14 season and in the 2014/15 season
Table 3: US RSV vaccines market forecast, 2016/17–2025/26
Table 4: Immunization coverage rates in the US, by risk group (%), 2016/17–2025/26
Table 5: France RSV vaccines market forecast, 2016/17–2025/26
Table 6: Immunization coverage rates in France, by risk group (%), 2016/17–2025/26
Table 7: Germany RSV vaccines market forecast, 2016/17–2025/26
Table 8: Immunization coverage rates in Germany, by risk group (%), 2015/16-2024/25
Table 9: Italy RSV vaccines market forecast, 2016/17–2025/26
Table 10: Immunization coverage rates in Italy, by risk group (%), 2016/17–2025/26
Table 11: Spain RSV vaccines market forecast, 2016/17–2025/26
Table 12: Immunization coverage rates in Spain, by risk group (%), 2016/17–2025/26
Table 13: UK RSV vaccines market forecast, 2016/17–2025/26
Table 14: Immunization coverage rates in the UK, by risk group (%), 2016/17–2025/26
Table 15: Synagis drug profile
Table 16: Synagis Phase III data in RSV
Table 17: Recommendations for palivizumab immunization by national authorities, 2018
Table 18: Synagis sales for RSV across the US and five major EU markets, by country ($m), 2016/17–2025/26
Table 19: Profiled pipeline products in development for RSV prophylaxis
Table 20: Ad26.RSV.preF drug profile
Table 21: Ad26.RSV.preF ongoing Phase I/II clinical trials in RSV vaccination
Table 22: Potential sales for RSV vaccines across the US and five major EU markets, by risk group ($m), 2016/17–2025/26
Table 23: ChAd155-RSV drug profile
Table 24: ChAd155-RSV completed clinical trial in RSV vaccination
Table 25: ChAd155-RSV ongoing clinical trial in RSV vaccination
Table 26: Potential sales for RSV vaccines in infants across the US and five major EU markets, by country ($m), 2016/17–2025/26
Table 27: GSK-3003891A drug profile
Table 28: GSK-3003891A completed Phase II clinical trials in RSV vaccination
Table 29: GSK-3003891A completed Phase II clinical trial in RSV vaccination
Table 30: Potential sales for RSV vaccines for pregnant women across the US and five major EU markets, by country ($m), 2016/17–2025/26
Table 31: RSV cps2 drug profile
Table 32: RSV delta NS2/delta 1313/I1314L drug profile
Table 33: RSV MEDI delta M2-2 backbone drug profile
Table 34: Summary of completed Phase I trials of RSV cps2, RSV D46/NS2/N/delta M2-2-HindIII, and RSV MEDI delta M2-2 for RSV infection
Table 35: Summary of ongoing Phase I trial of RSV delta NS2/delta 1313/I1314L and RSV MEDI delta M2-2 for RSV infection
Table 36: Potential sales for RSV vaccines in infants across the US and five major EU markets, by country ($m), 2016/17–2025/26
Table 37: MEDI8897 drug profile
Table 38: MEDI8897 Phase II clinical trial in RSV prophylaxis
Table 39: MEDI8897 Phase I trial data in RSV prophylaxis
Table 40: MVA-BN RSV drug profile
Table 41: MVA-BN RSV completed Phase I and Phase II clinical trials in RSV vaccination
Table 42: Potential sales for RSV vaccines in the elderly across the US and five major EU markets, by country ($m), 2016/17–2025/26
Table 43: RSV preF vaccine drug profile
Table 44: RSV preF vaccine Phase I/II trial data in RSV prophylaxis
Table 45: Potential sales for RSV vaccines in the elderly across the US and five major EU markets, by country ($m), 2016/17–2025/26
Table 46: RSV F vaccine profile
Table 47: RSV F vaccine Phase III Resolve data for RSV vaccination
Table 48: RSV F vaccine ongoing clinical trial in RSV vaccination
Table 49: RSV F vaccine key Phase II data in RSV vaccination
Table 50: Potential sales for RSV vaccines across the US and five major EU markets, by risk group ($m), 2016/17–2025/26
